GE Healthcare (GE) Acquires Zionexa
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall St futures retreat as oil gains on Mideast uncertainty, eyes on Trump-Xi talks
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- BTIG’s Krinsky warns 2000-like signals are mounting
- Plug Power COO resigns to join another company
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to Enable More Targeted Treatment for Metastatic Breast Cancer Patients
May 6, 2021 8:40 AM EDTGE Healthcare to scale Zionexas FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer Aims to make Cerianna available to 75% of metastatic breast cancer patients in the U.S. by 2023 Acquisition demonstrates GE Healthcares commitment to its precision health vision and builds additional pipeline of oncology and neurology tracers to help physicians personalize treatment
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- GE... More
